Form 4: Aytu BioPharma Executive Greg Pyszczymuka Reports Stock Transactions
SEC Form 4 Filing
Chief Commercial Officer Greg Pyszczymuka reports the vesting and conversion of restricted stock units into common shares of Aytu BioPharma.
Summary
- Greg Pyszczymuka, Chief Commercial Officer of Aytu BioPharma, reported a transaction involving restricted stock units (RSUs).
- On June 30, 2024, 208 RSUs vested and were converted into 208 common shares.
- Following the transaction, Pyszczymuka directly owns 22,976 common shares.
- The RSUs were granted on March 31, 2022, and vest quarterly from March 31, 2023, to March 31, 2025.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing reflecting scheduled vesting of stock options, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the conversion of existing equity awards.
Key Dates
| Date | Description |
|---|---|
| March 31, 2022 | Date the restricted stock units were granted. |
| March 31, 2023 | Start date for quarterly vesting of the restricted stock units. |
| June 30, 2024 | Date of the reported transaction where RSUs vested and converted to common shares. |
| March 31, 2025 | End date for quarterly vesting of the restricted stock units. |
| July 01, 2024 | Date of signature for the Form 4 filing. |
Keywords
Aytu BioPharma, Greg Pyszczymuka, insider trading, Form 4, stock transaction, restricted stock units, common shares, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.